pancraetic carcinoma pancreatic cancer
Conditions
Interventions
Everolimus will be administrated daily at a dose of 9 mg, devided into 2 doses.
Capecitabine is an orally administered fluoropirimidine. The dose will be 1000
mg/m2 twice daily for 2 weeks, with one
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Signed informed content obtained prior to treatment - Cytological or histological confirmed adenocarcinoma of the pancreas - Metastatic or non-resectable disease - Measurable lesion according to RECIST criteria - ECOG/ WHO performance 0-2 - Age > 18 years - Life expectancy > 3 months - Adequate renal function (creatinine 3.0 x 10 9/L, platelets > 100 x 10 9/L) - Mentally, physically, and geographically able to undergo treatment and follow up
Exclusion criteria
Exclusion criteria: - Clinical or radiological evidence of CNS metastases - Pregnancy (positive serum pregnancy test) and lactation - Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study will be six-month survival rate. | — |
Secondary
| Measure | Time frame |
|---|---|
| As secondary endpoints are defined: - Objective complete and partial response rate - Time to treatment failure - Overall survival - One year survival rate - Toxicity profile | — |
Countries
Netherlands
Outcome results
None listed